Journal article Open Access

Statistical review of Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report

Morris, Tim; Dahly, Darren; Hood, Kerry; Gates, Simon


DataCite XML Export

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="DOI">10.5281/zenodo.3928540</identifier>
  <creators>
    <creator>
      <creatorName>Morris, Tim</creatorName>
      <givenName>Tim</givenName>
      <familyName>Morris</familyName>
      <affiliation>MRC Clinical Trials Unit at University College London</affiliation>
    </creator>
    <creator>
      <creatorName>Dahly, Darren</creatorName>
      <givenName>Darren</givenName>
      <familyName>Dahly</familyName>
      <affiliation>HRB Clinical Research Facility Cork. Senior Lecturer in Patient-Focused Research Methods, School of Public Health, University College Cork</affiliation>
    </creator>
    <creator>
      <creatorName>Hood, Kerry</creatorName>
      <givenName>Kerry</givenName>
      <familyName>Hood</familyName>
      <affiliation>Centre for Trials Research, Cardiff University</affiliation>
    </creator>
    <creator>
      <creatorName>Gates, Simon</creatorName>
      <givenName>Simon</givenName>
      <familyName>Gates</familyName>
      <affiliation>Cancer Research UK Clinical Trials Unit, Institute of Cancer and Genomic Sciences, University of Birmingham, UK</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Statistical review of  Effect of Dexamethasone in Hospitalized Patients with COVID-19 –  Preliminary Report</title>
  </titles>
  <publisher>Zenodo</publisher>
  <publicationYear>2020</publicationYear>
  <subjects>
    <subject>COVID-19</subject>
    <subject>RCT</subject>
    <subject>Cinical trial</subject>
    <subject>Randomized controlled trial</subject>
    <subject>Dexamethasone</subject>
  </subjects>
  <dates>
    <date dateType="Issued">2020-07-02</date>
  </dates>
  <language>en</language>
  <resourceType resourceTypeGeneral="JournalArticle"/>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://zenodo.org/record/3928540</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsVersionOf">10.5281/zenodo.3928539</relatedIdentifier>
    <relatedIdentifier relatedIdentifierType="URL" relationType="IsPartOf">https://zenodo.org/communities/covid-19-tx-rct-stats-review</relatedIdentifier>
  </relatedIdentifiers>
  <version>1.0</version>
  <rightsList>
    <rights rightsURI="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">&lt;p&gt;The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical&amp;nbsp; trials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19 treatments,&amp;nbsp; independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at improving&amp;nbsp; both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our reviews&amp;nbsp; focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results, inferences). This&amp;nbsp; review reflects the expert opinions of the named authors, and does not imply endorsement by the MRC-NIHR Trials Methodology&amp;nbsp; Research Partnership, its wider membership, or any other organization. Here we review &lt;em&gt;Effect of Dexamethasone in Hospitalized Patients with COVID-19 &amp;ndash;&amp;nbsp; Preliminary Report &lt;/em&gt;by Horby &lt;em&gt;et al&lt;/em&gt;, published as a preprint on medRxiv on the 22nd of June, 2020.&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;Overall, this was a well-conducted, well-designed, practice-changing clinical trial providing the most convincing evidence to date of an efficacious treatment in hospitalised COVID-19 patients. However, there are a number of issues, primarily around the reporting of the trial, that should ideally be resolved prior to final publication. We also urge caution against over-interpreting the estimated subgroup-specific effects based on level of respiratory support, especially the suggestion of harm in the group not on oxygen or mechanical ventilation.&amp;nbsp;&lt;/strong&gt;&lt;/p&gt;</description>
  </descriptions>
</resource>
7,385
4,452
views
downloads
All versions This version
Views 7,3857,385
Downloads 4,4524,452
Data volume 2.8 GB2.8 GB
Unique views 6,5466,546
Unique downloads 3,9733,973

Share

Cite as